HALOZYME THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $2.38M, a 65.85% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $4.10M, a 55.61% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $2.45M, a 35.99% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was -$1.05M, a 267.95% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $7.88M, a 43.92% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $14.05M, a 12.08% increase from fiscal 2021.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $12.54M, a 80.22% decline from fiscal 2020.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $63.39M, a 345.68% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $7.88M 10-K · filed 2024-02-20 |
| 2023-09-30 | $4.10M 10-Q · filed 2023-11-06 | $12.47M derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-06-30 | $2.45M 10-Q · filed 2023-08-08 | $11.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-03-31 | -$1.05M 10-Q · filed 2023-05-09 | $12.38M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-12-31 | $6.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $14.05M 10-K · filed 2024-02-20 |
| 2022-09-30 | $2.64M 10-Q · filed 2023-11-06 | $11.39M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $3.82M 10-Q · filed 2023-08-08 | $13.40M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $624.00K 10-Q · filed 2023-05-09 | $13.76M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $12.54M 10-K · filed 2024-02-20 |
| 2021-09-30 | $4.65M 10-Q · filed 2022-11-08 | $20.97M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $4.18M 10-Q · filed 2022-08-09 | $28.87M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$602.00K 10-Q · filed 2022-05-10 | $43.07M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $63.39M 10-K · filed 2023-02-21 |
| 2020-09-30 | $12.55M 10-Q · filed 2021-11-02 | $58.78M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $18.38M 10-Q · filed 2021-08-09 | $48.30M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $19.72M 10-Q · filed 2021-05-10 | $34.39M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $14.22M 10-K · filed 2022-02-22 |
| 2019-09-30 | $2.08M 10-Q · filed 2020-11-02 | $8.16M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $4.47M 10-Q · filed 2020-08-10 | $9.62M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | -$449.00K 10-Q · filed 2020-05-11 | $8.29M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $13.72M 10-K · filed 2021-02-23 |
| 2018-09-30 | $3.54M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $3.14M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $4.98M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $12.78M 10-K · filed 2020-02-24 | |
| 2016-12-31 | $1.95M 10-K · filed 2019-02-21 | |
| 2015-12-31 | $13.10M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $6.79M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $5.08M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $1.68M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $4.75M 10-K · filed 2014-02-28 | |
| 2010-12-31 | $1.86M 10-K · filed 2013-03-01 | |
| 2009-12-31 | $1.02M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |